Reviewer’s report

**Title:** Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer

**Version:** 0  **Date:** 22 Nov 2017

**Reviewer:** Fatima Baltazar

**Reviewer's report:**

In the present study, the authors report data on the retrospective analysis of MCT1, MCT4 and their chaperone CD147 in 90 patients with endometrial cancer who underwent hysterectomy. The authors correlated the findings of the expression of these markers with clinico-pathological features and survival data.

The results are novel, since there are still no reports on the expression of these proteins in endometrial cancer. Also, the topic is relevant because these proteins are promising targets in cancer therapy and there is already one inhibitor of MCT1 which entered clinical trials.

The manuscript is written in a clear way, the methodology is adequate and the results support the conclusions.

Specific comments:

Methods. Immunohistochemical evaluation. Information on positive and negative controls used for IHC should be provided. The reason for choosing score 200 as the cut-off to distinguish between low and high expression should also be provided.

Results. The authors provide results for different patterns of MCT/CD147 expression in the tumour samples, however analysis of correlations with clinico-pathological features and survival data were only performed with the overall expression. MCT1 presents nuclear expression, which has already been described in soft tissue sarcomas has having prognostic significance. What is the significance of MCT1 nuclear expression in endometrial cancer? Did the authors perform the analysis?

**Are the methods appropriate and well described?**
If not, please specify what is required in your comments to the authors.

Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organisation that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.
I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal